Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
SkyePharma finalizes UKP 35 million financing, updates potential sale of injectable business
January 29th, 2007
SkyePharma PLC (SKYE) announced that it has finalized a UKP 35 million (US$68.57 million) financing agreement and provides an update on the continuing progress with the Flutiform development and the potential sale of the Injectable Business. The group has entered into an agreement with a specialist lending entity headquartered in Ireland and advised by Christofferson, Robb & Company (CRC) for a 10-year secured amortizing loan facility of approximately UKP 35 million. The facility comprises initial commitments of US$35 million and UKP 26.5 million repayable over 10 years based on a minimum amortization schedule. This schedule is based on expected...
Source: Biotech Business Week (2007-01-29)
|
